Clinical Trial Update: A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A multicenter Phase II randomized trial comparing BIBF 1120 (nintedanib), BIBW 2992 (afatinib), and sequential administration of the two in hormone-resistant pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Afatinib (afatinib)
• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2015-01-15